[6-K] Chemomab Therapeutics Ltd. American Depositary Share Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Chemomab Therapeutics Ltd. furnished a Form 6-K for August 2025 reporting the inclusion of three exhibits related to its second quarter of 2025. The filing states it includes unaudited condensed consolidated financial statements for the three and six months ended June 30, 2025, the companys Managements Discussion and Analysis of financial condition and results of operations for those periods, and a press release dated August 14, 2025 titled "Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update." The exhibits (99.1, 99.2, 99.3) and interactive financial data files are designated and will be deemed incorporated by reference into specified Form F-3 and Form S-8 registration statements. The report is signed by the Chief Financial Officer, Sigal Fattal.

Positive

• Unaudited condensed consolidated financial statements for the three- and six-month periods ended June 30, 2025 are furnished as Exhibit 99.1, indicating timely interim financial disclosure.
• Managements Discussion and Analysis is furnished as Exhibit 99.2, providing narrative context to the financial statements and operational results.

Negative

• The Form 6-K text does not include any financial figures or metrics; numeric results are only available within the referenced exhibits and press release.

Insights

Financial Analyst

TL;DR: Routine 6-K disclosing Q2-2025 financial statements, MD&A, and a corporate-update press release; no numeric results included in the 6-K text.

The filing confirms delivery of unaudited interim financial statements and related MD&A for the three- and six-month periods ended June 30, 2025, plus a press release dated August 14, 2025 announcing Q2 results. For investors, the 6-K signals timely disclosure and incorporation of the detailed materials into prior registration statements, enabling access to the full financial detail via the exhibits. Because this cover filing does not reproduce financial metrics, material assessment depends on reviewing the attached exhibits.

Corporate Governance Expert

TL;DR: Disclosure practices appear compliant; exhibits are incorporated by reference into registration statements, supporting regulatory transparency.

The document is procedural and indicates the company provided interim financial statements, MD&A, and a press release, and explicitly incorporated those exhibits by reference into specified Form F-3 and S-8 filings. Signature by the CFO is included. From a governance standpoint, this demonstrates adherence to periodic reporting and SEC incorporation conventions; the filing itself contains no evaluative commentary or governance changes.

false--12-31Q20001534248

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number 001-38807

CHEMOMAB THERAPEUTICS LTD.
(Translation of registrant’s name into English)

6 Habarzel Street, Building C, 10th Floor, Tel-Aviv, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒           Form 40-F ☐

EXPLANATORY NOTE

Chemomab Therapeutics Ltd. (the “Company”) hereby furnishes under this Report of Foreign Private Issuer on Form 6-K (the “Form 6-K”) the following: (i) unaudited condensed consolidated financial statements of the Company as of and for the three and six-months ended June 30, 2025, as Exhibit 99.1 to this Form 6-K; (ii) Management’s Discussion and Analysis of Financial Condition and Results of Operations, which discusses and analyzes the Company’s operational and financial condition and results of operations as of and for the three and six-month period ended June 30, 2025, as Exhibit 99.2 to this Form 6-K; and (iii) a press release, dated August 14, 2025, titled “Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update,” as Exhibit 99.3 to this Form 6-K.

Exhibits 99.1, 99.2 and 99.3 to this Report on Form 6-K shall be deemed to be incorporated by reference into Company’s Registration Statements on Form F-3 (File No. 333-275002 and No. 333-281750) and Form S-8 (File No. 333-259489 and No. 333-266868).

EXHIBIT INDEX

Exhibit		Description
99.1		Unaudited Condensed Consolidated Financial Statements for the three and six months ended June 30, 2025.
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations.
99.3		Press Release dated August 14, 2025, titled “Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update”.
101		Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Unaudited Interim Consolidated Balance Sheets, (ii) Unaudited Interim Consolidated Statements of Operations, (iii) Unaudited Interim Consolidated Statements of Comprehensive Loss, (iv) Unaudited Consolidated Statements of Redeemable Convertible Preferred Shares and Changes in Shareholders’ Equity (v) Unaudited Consolidated Statements of Cash Flows and (vi) related notes to these consolidated financial statements.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CHEMOMAB THERAPEUTICS LTD.
Date: August 14, 2025	By:	/s/ Sigal Fattal
		Sigal Fattal
		Chief Financial Officer

FAQ

What did Chemomab (CMMB) file in this Form 6-K?

The company furnished three exhibits: 99.1 unaudited condensed consolidated financial statements for the three- and six-month periods ended June 30, 2025; 99.2 Managements Discussion and Analysis for those periods; and 99.3 a press release dated August 14, 2025 announcing second quarter 2025 financial results and a corporate update.

Are the Q2 2025 financial statements included in the filing?

Yes. The filing states that unaudited condensed consolidated financial statements for the three- and six-month periods ended June 30, 2025 are furnished as Exhibit 99.1.

Does the Form 6-K itself report numerical earnings or revenue figures?

No. The Form 6-K text references exhibits containing the financial results but does not present numerical financial figures within the cover report.

Were the exhibits incorporated by reference into other filings?

Yes. Exhibits 99.1, 99.2 and 99.3 are stated to be deemed incorporated by reference into the companys Form F-3 (File Nos. 333-275002 and 333-281750) and Form S-8 (File Nos. 333-259489 and 333-266868) registration statements.

Who signed the Form 6-K?

The report is signed by Sigal Fattal, Chief Financial Officer, on behalf of Chemomab Therapeutics Ltd.